Meanwhile, Nel et al. [7] revealed that insulin-like growth factor binding protein (IGFBP)-1 mRNA level was correlated with the time to progression (TTP) by detecting CTCs in HCC patients undergone selective internal radiotherapy (SIRT), supporting that CTCs can be a new molecular marker for individualized treatment of HCC. This evidence concerns the gene IGFBP1 and hepatocellular carcinoma.